Raptor Pharmaceutical Corp		
Form 8-K		
November 06, 2012		
UNITED STATES		
SECURITIES AND EXCHANGE COMMIS	SSION	
Washington, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the Securi	ities Exchange Act of 1934	
Date of Report (Date of earliest event report	ed): November 5, 2012	
RAPTOR PHARMACEUTICAL CORP.		
(Exact name of registrant as specified in its o	charter)	
Delaware	000-25571 86-0883978	
(State or other jurisdiction of incorporation)	(Commission File Number) (IRS Employer Identif	fication No.)
9 Commercial Blvd., Suite 200, Novato, Cal (Address of principal executive offices and 2		
Registrant's telephone number, including are	ea code: (415) 382-8111	
(Former name or former address, if changed	since last report)	
	n 8-K filing is intended to simultaneously satisfy the ovisions (see General Instruction A.2. below):	e filing obligation of
[] Soliciting material pursuant to Rule 14a-1 [] Pre-commencement communications pursuant	e 425 under the Securities Act (17 CFR 230.425) 12 under the Exchange Act (17 CFR 240.14a-12) suant to Rule 14d-2(b) under the Exchange Act (17 suant to Rule 13e-4(c) under the Exchange Act (17	

Item 8.01 Other Events.

On November 5, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, presented on Saturday, November 3rd a "Late Breaking" poster entitled "Extended Treatment with RP 103 in Patients with Nephropathic Cystinosis" at Kidney Week 2012, presenting data from the Company's RP103 (cysteamine bitartrate delayed-release) extension study.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits

(d)	Exhibits.		
		Filed	
Exhib	it	Here Incorporated by Reference	
No.	Exhibit Description	with FormFile No.Exhibit Filing Date	Filed By
99.1	Press release issued by the Company dated as of November 5, 2012	X	

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### RAPTOR PHARMACEUTICAL CORP.

Date: November 5, 2012

By: /s/ Christopher M. Starr, Ph.D.

Name: Christopher M. Starr, Ph.D.

Title: Chief Executive Officer and Director

# Exhibit Index

		Filed	
Exhibi	t	Here Incorporated by Reference	
No.	Exhibit Description	with FormFile No.Exhibit Filing Date	Filed By
99.1	Press release issued by the Company dated as of November 5, 2012	X	